Compugen Ltd.
NASDAQ:CGEN
Overview | Financials
Company Name | Compugen Ltd. |
Symbol | CGEN |
Currency | USD |
Price | 2.43 |
Market Cap | 217,573,452 |
Dividend Yield | 0% |
52-week-range | 1.35 - 3.03 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Anat Cohen-Dayag Ph.D. |
Website | https://cgen.com |
About Compugen Ltd.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD